| Date |
Event |
Presentation |
Speakers |
|
April 6, 2013
|
AACR Annual Meetings
|
Drug Discovery in Industry, Academia, and Government: What Is the Track Record?
|
Michael A. White
|
|
|
|
Clinical Trial Design in the Genomic Era Co-Chairpersons: Donald A. Berry, The University of Texas MD Anderson Cancer Center, Houston, TX, and George W. Sledge, Jr., Stanford University School of Medicine, Stanford, CA
|
Donald Berry
|
|
|
|
Rational Combination Therapies in Cancer Chairperson: Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Gordon Mills
|
|
|
|
Bridging the Gap Between Clinical Research and Laboratory Investigation: Utilizing Presurgical Clinical Trials to Investigate Anti-CTLA-4 Immunotherapy Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Padmanee Sharma
|
|
|
|
Whole Body Metabolism and Cancer Chairperson: Philipp E. Scherer, UT Southwestern Medical Center, Dallas, TX
|
Philipp Scherer
|
|
|
|
Tumor-Secreted Factors Chairperson: David C. Lyden, Weill Cornell Medical College of Cornell University, New York, NY
|
George A. Calin
|
|
|
|
Identifying Novel Redox Signaling Pathways for Cancer Chemoprevention: From Fly to the Mouse Garth Powis, The University of Texas MD Anderson Cancer Center, Houston, TX
|
Garth Powis
|
|
|
|
PAK Family of Kinases in Human Cancer: Past, Present, and Future Rakesh Kumar, George Washington University, Washington, DC
|
Rakesh Kumar
|
|
February 24, 2011
|
Targeting P13K / mTOR Signaling in Cancer
|
Session 2 | PI3K Pathway Aberrations in Human Cancer
|
Gordon Mills
|
|
|
|
mTORC1 regulation by TSC2
|
Cheryl Lyn Walker
|
|
|
|
Predictors and pharmacodynamic markers of rapamycin response
|
Funda Meric-Bernstam
|
|
|
|
Session 4 | Targeting mTOR
|
Funda Meric-Bernstam
|
|
|
|
Targeting the PI3K/AKT/mTOR pathway in the clinic: Early results from the PREDICT program
|
Razelle Kurzrock
|
|
|
|
Session 8 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials II
|
Funda Meric-Bernstam
|
|
|
|
Overcoming challenges to targeting the PI3K pathway in cancer
|
Gordon Mills
|
|
|
|
Molecular marker-based clinical trial designs to target the PI3K pathway
|
Ana Gonzalez-Angulo
|
|
|
|
Session 7 | Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials I
|
Funda Meric-Bernstam
|
|
February 13, 2011
|
Inositide Signaling in Pharmacology and Disease (X1)
|
PI 3-Kinases (X2) | Workshop 1: Monitoring Phosphoinositide Activation in Signaling and Disease
|
Gordon Mills
|
|
|
|
PI 3-Kinases (X2) | A Systems Biology Approach to Monitor the PI3K Pathway
|
Gordon Mills
|
|
October 12, 2008
|
15th North American Regional Meeting - International Society for the Study of Xenobiotics
|
Crystallographic Studies of CYP46A1
|
Irina A. Pikuleva
|
|
May 30, 2008
|
ASCO Annual'08 Meeting
|
breast cancer-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
cancer genetics-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
|
cancer prevention/epidemiology-- Single Nucleotide Polymorphisms, Clinical Trials, and Tobacco Research: Search for the Smoking Gun
|
Margaret R. Spitz
|
|
|
|
cancer prevention/epidemiology-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
developmental therapeutics-- c-MET Inhibition for Cancer Treatment
|
Razelle Kurzrock
|
|
|
|
developmental therapeutics-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
|
developmental therapeutics-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
gastrointestinal (colorectal) cancer-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
|
gastrointestinal (colorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
|
gastrointestinal (noncolorectal) cancer-- Intraperitoneal Treatment for Gastrointestinal Cancer: Role of Debulking and Chemotherapy
|
Cathy Eng
|
|
|
|
gastrointestinal (noncolorectal) cancer Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
genitourinary cancer-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies CPO20A)
|
Paul Mathew
|
|
|
|
genitourinary cancer What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
|
|
|
gynecologic cancer-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
lung cancer-- Therapeutic Modalities for “Small” Stage I Lung Cancers
|
Robert Timmerman
|
|
|
|
lymphoma and plasma cell disorders-- The Role of Maintenance Therapy in Follicular Lymphoma: Pros and Cons
|
Peter McLaughlin
|
|
|
|
patient and survivor care-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
patient and survivor care-- Picking the Winners Through Biomarker Enrichment: Could This Be the End of Phase III Trials?
|
Chris H. Takimoto
|
|
|
|
sarcoma/bone and soft tissue cancers-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
tumor biology-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
meet the professor sessions-- Advances in Anal Cancer Management (M01)
|
Cathy Eng
|
|
|
|
meet the professor sessions-- Issues in the Modulation of Angiogenesis Pathways (M10)
|
Roy S. Herbst
|
|
|
|
meet the professor sessions-- Practical Aspects of Intraperitoneal Chemotherapy Administration (M20)
|
Maurie Markman
|
|
|
|
meet the professor sessions-- Postmenopausal Hormone Therapy: Friend or Foe? (M19)
|
Peter Ravdin
|
|
|
|
meet the professor sessions-- Management of Soft Tissue Sarcoma for the Community Oncologist (M12)
|
Shreyaskumar Patel
|
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07A)
|
James C. Yao
|
|
|
|
clinical problems in oncology-- Management of Neuroendocrine Cancers: Radiopharmaceuticals, Novel Therapies, and the Impact of Octreotide (CPO07B)
|
James C. Yao
|
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20A)
|
Paul Mathew
|
|
|
|
clinical problems in oncology-- What to Do for the Prostate Cancer Patient with a Rising Prostate-Specific Antigen and No Disease on Imaging Studies (CPO20B)
|
Paul Mathew
|
|
October 16, 2007
|
Inaugural HDAC inhibitors: Meeting the Challenges of Chemical Development of HDAC Inhibitors Oct (16 -17)
|
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT(11:10-16:30)
|
Madeleine Duvic
|
|
|
|
MOLECULAR MODE-OF-ACTION AND BIOMARKER STRATEGIES FOR CLINICAL DEVELOPMENT: Panel Discussion- Are HDAC Inhibitors Proving Their Worth in the Clinic? (14:25-15:25)
|
Madeleine Duvic
|
How We Rank